3 results
Approved WMOCompleted
To determine the MTD toxicity of standard dose cetuximab together with concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine.
Approved WMORecruiting
To determine the objective response rate of entrectinib, as assessed by BICR, in each patient population basket of solid tumors that harbor anNTRK1/2/3, ROS1, or ALK gene rearrangement
Approved WMOCompleted
Primary: to compare the OSS concept with RCM in the surgical treatment of BCCs with current standard of care.Secondary: to assess the accuracy (sensitivity and specificity) of diagnosing BCC by comparing RCM with punch biopsy as diagnostic tools.…